Ifosfamide

Generic Name: Ifosfamide

Brand Names: Ifex

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 3778-73-2

Unique Ingredient Identifier: UM20QQM95Y

Background: Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication: Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...

Associated Conditions: Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy in Treating Patients With Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: Filgrastim (G-CSF)
Biological: Bleomycin Sulfate (BLM)
Biological: Recombinant Interferon Alfa
Drug: Carmustine
Drug: Cytarabine (ARA-C)
Drug: Cisplatin (CDDP)
Drug: Etoposide (VP-16)
Drug: Cyclophosphamide
Drug: Ifosfamide
Drug: Idarubicin
Drug: Melphalan
Drug: Leucovorin Calcium
Drug: mitoxantrone hydrochloride (DHAD)
Drug: Methotrexate
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Methylprednisolone
Drug: Vincristine Sulfate
Radiation: Radiation Therapy

First Posted Date: 2003-04-16

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 116

Registration Number: NCT00002835

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Phase 2

Terminated

Conditions: Childhood Diffuse Large Cell Lymphoma
Childhood Immunoblastic Large Cell Lymphoma
Recurrent Childhood Large Cell Lymphoma
B-cell Childhood Acute Lymphoblastic Leukemia
L3 Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Lymphoblastic Leukemia
Childhood Burkitt Lymphoma
Recurrent Childhood Lymphoblastic Lymphoma
Recurrent Childhood Small Noncleaved Cell Lymphoma

Interventions: Drug: ifosfamide
Drug: etoposide
Biological: rituximab
Drug: carboplatin
Biological: filgrastim
Drug: methotrexate
Drug: cytarabine
Other: laboratory biomarker analysis

First Posted Date: 2003-04-09

Last Posted Date: 2013-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 82

Registration Number: NCT00058461

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors

Phase 1

Completed

Conditions: Ovarian Cancer
Testicular Germ Cell Tumor
Extragonadal Germ Cell Tumor

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: etoposide
Drug: ifosfamide
Drug: paclitaxel
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2016-05-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 108

Registration Number: NCT00002558

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Phase 2

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-19

Lead Sponsor: Medical Research Council

Target Recruit Count: 120

Registration Number: NCT00040690

Locations: 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom

Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer

Phase 2

Completed

Conditions: Testicular Germ Cell Tumor

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-19

Lead Sponsor: Medical Research Council

Target Recruit Count: 25

Registration Number: NCT00004077

Locations: 🇬🇧
Velindre Hospital, Cardiff, Wales, United Kingdom

Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-04

Lead Sponsor: Medical Research Council

Target Recruit Count: 600

Registration Number: NCT00003159

Locations: 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
🇬🇧
Royal Marsden NHS Foundation Trust - Surrey, Sutton, England, United Kingdom

Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors

Phase 2

Completed

Conditions: Ovarian Cancer
Sarcoma
Small Intestine Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-04

Lead Sponsor: Societe Internationale d'Oncologie Pediatrique

Registration Number: NCT00025441

Locations: 🇬🇧
Saint Bartholomew's Hospital, London, England, United Kingdom
🇬🇧
Bristol Royal Hospital for Children, Bristol, England, United Kingdom
🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom

and more 18 locations